Background: The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine.
Introduction
The risk of peripartum HIV transmission can be reduced from 25 to 12% by the administration of a single dose of nevirapine to an HIV-infected, pregnant woman in labor and to her infant at birth [1] . More effective antiretroviral regimens for the prevention of mother-to-child transmission (PMTCT) are now recommended [2, 3] , and access to such regimens is steadily improving [4] . However, in settings with incomplete access to comprehensive antiretroviral therapy (ART), or when women are ART ineligible, ease of administration and low cost have resulted in the use of single-dose nevirapine (sdNVP) by at least 1.5 million women worldwide, including at least 340 000 women in South Africa [2, 5, 6] .
Exposure to sdNVP may result in HIV mutations which confer resistance to nevirapine and efavirenz, two nonnucleoside reverse transcriptase inhibitors (NNRTIs) that form the basis of first-line ART in most resource-limited settings [7] . As a result, sdNVP exposure may reduce the effectiveness of the antiretroviral regimen most likely to be available when women later require therapy for their own HIV disease [2, 5, 8, 9] . The OCTANE trial randomized women with screening CD4 cell count below 200/ml, with sdNVP exposure (trial 1) and without sdNVP exposure (trial 2), to initiate either nevirapine or lopinavir/ritonavirbased ART. Among sdNVP-exposed women (trial 1), the lopinavir/ritonavir arm demonstrated significantly lower rates of virologic failure or death than the nevirapine arm [10] . Revised 2010 WHO treatment guidelines now recommend protease inhibitor-based ART for women initiating ART within 12 months of sdNVP exposure [11] . However, because lopinavir/ ritonavir is currently 12 times more expensive than nevirapine [12] , policy makers must consider whether lopinavir/ritonavir provides sufficient health benefits in first-line ART to warrant its additional cost. Our objective was to evaluate the cost-effectiveness of firstline lopinavir/ritonavir compared to first-line nevirapine-based ART in a cohort of women with prior sdNVP exposure.
Methods Overview
We used a published computer simulation model of HIV infection [13] , with data from OCTANE trial 1 [10] and cohorts in South Africa [14, 15] , to project the outcomes of initial antiretroviral regimens among sdNVP-exposed women. In addition to a no ART strategy, we evaluated the two specific ART strategies examined in the OCTANE trial: first-line nevirapine followed by second-line lopinavir/ritonavir, and first-line lopinavir/ritonavir followed by second-line nevirapine.
For each strategy, we projected life expectancy, opportunistic infections, and HIV-related healthcare costs. Outcomes were evaluated in the short term (2-5 years) and over patient lifetimes to calculate cost-effectiveness ratios of alternative ART strategies. Incremental costeffectiveness ratios were expressed in 2008 US$/year of life saved (YLS), with costs converted from South African Rand (ZAR) at the 2008 average exchange rate (1 USD ¼ 8.2612 ZAR) [16] . All costs and health benefits were discounted at 3% annually [17] . Assuming a modified societal perspective, patients' costs for time, transportation, and child care were excluded [17] . The World Health Organization (WHO) suggests that health interventions be considered 'very cost-effective' if their cost per quality-adjusted life year is less than a country's per capita gross domestic product [18] (GDP: $5700 for South Africa in 2008 [19] ). Due to limited HIV-related quality-of-life data in Africa, we computed costeffectiveness ratios in $/YLS rather than in $/qualityadjusted YLS, thereby using WHO thresholds as general guidance only.
Model
The Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International model for South Africa is a first-order Monte Carlo simulation of HIV infection (Supplementary Appendix, http://links.lww.com/ QAD/A104) [13, 20] . HIV-infected women are simulated individually from model entry through death. Disease progression is characterized by a sequence [21, 22] . To reflect resource availability in many settings in which sdNVP is commonly used, HIV RNA monitoring was assumed to be unavailable. The first antiretroviral regimen included either lopinavir/ritonavir or nevirapine with tenofovir/emtricitabine, representing the ART regimens evaluated in the OCTANE trial. Patients were switched from the first to second antiretroviral regimen after observed clinical or immunologic failure, defined as at least one severe opportunistic infection (defined in Table 1 ) or an at least 50% decrease from the peak on-ART CD4 cell count [23] . The second 'line' of ART included either nevirapine (following first-line lopinavir/ritonavir) or lopinavir/ritonavir (following first-line nevirapine) with didanosine/zidovudine. Reflecting practice at several OCTANE sites, women who failed either second-line regimen (defined as the observation of three severe opportunistic infections or an at least 90% decrease from the peak on-ART CD4 cell count) received a lifelong 'third-line/ maintenance' regimen of lopinavir/ritonavir with lamivudine [21, 24, 25] .
Model input parameters
Baseline cohort characteristics were those of OCTANE trial 1 participants, including mean age (31 years), CD4
(135 /ml), and HIV RNA level (5.10 log 10 copies/ml), and median time from sdNVP exposure (17 months) ( Tables 1 and 2 ) [10] .
Antiretroviral therapy efficacy
We defined the efficacy of each antiretroviral regimen as the 24-week rate of HIV RNA suppression to less than 400 copies/ml. For both first-line regimens, we used OCTANE trial 1 data to derive 24-week efficacies (nevirapine: 85%, lopinavir/ritonavir: 97%), 24-week CD4 gains on each suppressive regimen, yearly risks of virologic failure more than 24 weeks after ART initiation, and risks of severe toxicity. Second-line ART outcomes were not available from OCTANE. For second-line nevirapine following first-line lopinavir/ ritonavir, we derived the base case efficacy estimate (43%) as the midpoint of estimates from Europe (41.5%) [26] and South Africa (45%) [27] . Data from South Africa and Malawi informed the 24-week efficacy of secondline lopinavir/ritonavir following first-line nevirapine (72%) [27, 28] .
OCTANE subgroup analyses
To examine the impact of NNRTI resistance, the OCTANE trial also stratified participants by presence or absence of resistance detectable at ART initiation by standard genotype assays, and time between sdNVP exposure and ART initiation [7] . First-line ARTefficacies demonstrate smaller benefits of lopinavir/ritonavir compared to nevirapine in subgroups with lower rates of known or probable NNRTI resistance ( Table 1) . We examined the cost-effectiveness of each first-line ART regimen in the OCTANE subgroups, as well as of a strategy in which first-line ART was selected based on detected NNRTI resistance (Appendix).
Sensitivity analyses
In sensitivity analyses, we varied clinical and cost parameters, ART switching and discontinuation strategies, and third-line ARTavailability. We examined in detail the impact of access to HIV RNA monitoring at 3-monthly and 6-monthly intervals to facilitate earlier switching from first to second-line ART (Appendix). To describe the effects of simultaneous variations in multiple parameters, we performed multiway sensitivity analyses; created 'best-case' and 'worst-case' clinical scenarios for first-line lopinavir/ritonavir, incorporating the highest and lowest published values for key model parameters ( Table 1 , bottom); and assigned available trial 2 results (non-sdNVP-exposed women) to trial 1 participants (Appendix).
Role of the funding source
The funding sources had no role in study design; collection, analysis, or interpretation of data; manuscript preparation; or decision to submit the paper for publication. In the short term, nevirapine-based ARTwas projected to save money compared to no ART. For example, at 2 years after initiation, first-line nevirapine reduced projected opportunistic infections (123 versus 222 opportunistic infections/100 person-years) and improved projected survival (94.7 versus 33.6%) compared to no ART, yet was also cost-saving ($1930 versus $2150/person). Projected survival benefits of the first-line nevirapine strategy compared to no ART persisted indefinitely, and projected cost savings persisted from 1-3 years after ART initiation.
Long-term projections
Providing no ART resulted in a projected life expectancy of 1.6 years, at a cost of $2980/person. Initiating first-line nevirapine-based ART increased projected life expectancy to 15.2 years and cost to $13 990/person, leading to a costeffectiveness ratio of $810/YLS, compared to no ART.
First-line lopinavir/ritonavir-based therapy increased life
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Subgroup analyses
The cost-effectiveness ratio of first-line lopinavir/ ritonavir compared to first-line nevirapine was $5650/ YLS for OCTANE participants with no detectable NNRTI resistance at baseline ( Table 4 , Section B). For women with baseline NNRTI resistance and for women exposed to sdNVP 6-12 months prior to ART initiation, first-line nevirapine represented an inefficient use of resources compared to first-line lopinavir/ritonavir ( Person-time at risk assumes deaths occur at mid-point of month in which they occur. Extended dominance: In the subgroup with baseline NNRTI resistance and the subgroup of women initiating ART within 6-12 months after sdNVP, the costeffectiveness ratio of the 1st-line LPV/r strategy compared to 1st-line NVP is less than the cost-effectiveness ratio of 1st-line NVP compared to no ART. This indicates that the 1st-line NVP strategy represents an inefficient use of healthcare resources, if LPV/r is available. By convention in these cases, the cost-effectiveness ratio of 1st-line NVP compared to no ART is not reported. By the same mechanism, in the 'worst-case' clinical scenario for 1st-line LPV/r, 1st-line LPV/r represents an inefficient use of resources compared to 1st-line NVP, and the cost-effectiveness ratio of 1st-line LPV/r compared to no ART is not shown. c Strong dominance occurs in the subgroup with sdNVP exposure >24 months prior to ART initiation because 1st-line LPV/r is both less effective and more expensive than 1st-line NVP. The cost-effectiveness ratios in the 'best-case' scenario are presented without rounding, to demonstrate that 1st-line nevirapine is not dominated. However, the nearly equivalent cost-effectiveness ratios of 1st-line NVP compared to no ART and of 1st-line LPV/r compared to 1st-line NVP suggest that, if all of the most favorable parameters for 1st-line LPV/r were true, any program able to afford 1st-line NVP-based ART would achieve greater health benefits at nearly the same cost by instead choosing 1st-line LPV/r. f First-line ART switched to second-line ART for a one-log increase in RNA or return to peak pre-ART RNA value. Shown are scenarios in which HIV RNA monitoring was performed every 6 months; results of 3-monthly RNA monitoring or RNA monitoring applied only to 1st-line NVP strategy are not substantially different. Lower life expectancy in the 1st-line lopinavir/ritonavir strategy with RNA monitoring, compared to the base case, results from earlier switching to a less effective 2nd-line regimen (2nd-line NVP, efficacy 43%).
$585 would be a more efficient use of resources than firstline NVP for all women ( Table 4 , section C).
Sensitivity analyses
The 24-week suppressive ART efficacies and the risk of 'late' virologic failure after 24 weeks on lopinavir/ ritonavir-based ART had the greatest impact on the costeffectiveness of first-line lopinavir/ritonavir (Fig. 1 ). Holding all other parameters equal to the base case, firstline nevirapine efficacy needed to be 97% or less, secondline nevirapine efficacy at least 13%, first-line lopinavir/ ritonavir efficacy at least 89%, second-line lopinavir/ ritonavir efficacy 87% or less, or lopinavir/ritonavir 'late' failure risk 8.97%/year or less (1.64%/year lower than nevirapine 'late' failure), for the cost-effectiveness ratio of first-line lopinavir/ritonavir to remain below $5700/YLS (South African GDP).
The cost-effectiveness ratio for first-line lopinavir/ ritonavir remained below $5700/YLS even if the cost of lopinavir/ritonavir was more than twice its current value (Fig. 1) , as well as if HIV RNA monitoring was available ( Table 4 ). Results were robust to wide variations in CD4 cell counts at sdNVP receipt and ART initiation; incidence and severity of nevirapine-related toxicity; ART monitoring, switching, and stopping strategies; and composition and availability of third-line ART ( Supplementary Table 2 , http://links.lww.com/QAD/A104). The influence of second-line ART efficacy on cost-effectiveness results was greatest when the prevalence of baseline NNRTI resistance was very low (Fig. 2) .
Additional multiway sensitivity analyses indicated that using 'worst-case' parameter values for the first-line lopinavir/ritonavir strategy led first-line lopinavir/ritonavir to be dominated by first-line nevirapine ( Table 4 , section C). 'Best-case' values for first-line lopinavir/ ritonavir rendered the cost-effectiveness ratio of lopinavir/ritonavir compared to nevirapine similar to that of nevirapine compared to no ART ($810/YLS). When both lopinavir/ritonavir first-line efficacy (93%) and 'late' failure risk (8.08%/year) from trial 2 were applied to trial 1 participants (but not when each parameter was applied alone), lopinavir/ritonavir cost-effectiveness was substantially reduced (Appendix).
Discussion
We report model-based projections of clinical outcomes and costs for South African women, similar to OCTANE trial 1 participants, initiating ART a median of 17 months after sdNVP exposure for PMTCT. From 1 to 3 years after ART initiation, nevirapine-based first-line ART is projected to improve survival and save money compared to the use of no ART. Short-term cost savings stem from the marked reduction in opportunistic infections and death associated with nevirapine-based ART compared Fig. 2 . Two-way sensitivity analyses depicting the simultaneous impact of the prevalence of nonnucleoside reverse transcriptase inhibitor resistance at baseline and the efficacy of the second-line ART in suppressing HIV RNA to below 400 copies/ml at 24 weeks. In both panels, the vertical axis indicates the cost-effectiveness ratio for first-line LPV/r compared to first-line NVP in $/YLS. The vertical axis should be understood to extend beyond the $18 000/YLS mark, to include situations in which first-line LPV/r is 'dominated' by first-line NVP. The shaded regions indicate a cost-effectiveness ratio of less than $5700/YLS. In panel (a), the horizontal axis represents varying values for second-line NVP efficacy. The dashed line indicates the OCTANE cohort in whom no NNRTI resistance was detected by standard genotypic resistance testing at the time of ART initiation. In this group, second-line NVP efficacy must be at least 44% (square) for the first-line LPV/r cost-effectiveness ratio to fall below $5700. The dotted line indicates the base case scenario for the entire OCTANE cohort, in whom the prevalence of NNRTI resistance at baseline was 14%. For this group, second-line NVP efficacy must be at least 13% (circle) for the first-line LPV/r cost-effectiveness ratio to fall below $5700. The solid line indicates the OCTANE cohort in whom NNRTI resistance was detected at baseline. For this group, first-line LPV/r is economically preferred to first-line NVP at all values of second-line NVP efficacy, due to 'extended dominance'. The costeffectiveness ratios of LPV/r compared to no ART are displayed in the Figure. In panel (b) , the horizontal axis represents values for second-line LPV/r efficacy. In the OCTANE cohort in whom no baseline NNRTI resistance was detected (dashed line) second-line LPV/r efficacy must be 73% or less (square) for the first-line LPV/r cost-effectiveness ratio to fall below $5700. In the entire OCTANE cohort (14% baseline resistance, dotted line), second-line LPV/r efficacy must be 87% or less (circle) for the first-line LPV/ r cost-effectiveness ratio to fall below $5700. For the group in whom NNRTI resistance was detected at baseline (solid line), firstline LPV/r is again economically preferred to first-line NVP at all values of second-line LPV/r efficacy, due to 'extended dominance' and as a result the cost-effectiveness ratio of LPV/r compared to no ART is displayed in the Figure. to no ART; costs averted in opportunistic infection and end-of-life care offset the costs of nevirapine-based ART itself. By reducing risk for early virologic failure, use of first-line lopinavir/ritonavir instead of first-line nevirapine adds modest short-term benefit and cost, improving 5-year survival from 86.7 to 92.1% at an additional cost of $910/person. In projections beyond 3 years, providing nevirapinebased ART becomes more expensive than providing no ART, due to the prolonged medication and care costs accrued during markedly longer life expectancies (15.2 vs. 1.6 years). By WHO guidance, this substantial survival benefit from nevirapine-based ART would be 'very cost-effective' compared to no ART (costeffectiveness ratio: $810/YLS). First-line lopinavir/ ritonavir further increases life expectancy to 16.3 years, with a higher cost-effectiveness ratio ($1520/YLS) compared to first-line nevirapine. This suggests that for HIV programs able to afford higher per-person costs for HIV care ($4680 vs. $ 3770 at 5 years; $15 630 vs. $13 990 over patient lifetimes), first-line lopinavir/ritonavir provides excellent value for sdNVP-exposed women.
These findings confirm modeling work conducted before OCTANE data were available [29] and are robust to plausible variations in HIV RNA monitoring availability and frequency, lopinavir/ritonavir cost, nevirapine toxicity, CD4 cell counts, and availability of third-line ART. However, three factors influence the cost-effectiveness of first-line lopinavir/ritonavir: first-line lopinavir/ritonavir efficacy, long-term ART outcomes, and NNRTI resistance at ART initiation.
First-line lopinavir/ritonavir remains 'very cost-effective' compared to nevirapine unless its 24-week suppressive 'efficacy' is below 89% (holding first-line nevirapine efficacy at 85%). Whereas OCTANE trial 1 demonstrated a 24-week efficacy far above this threshold (97%), other trials have suggested 24-week intention-to-treat lopinavir/ritonavir efficacies ranging from 65 to 93% in treatment-naïve women without sdNVP exposure [30, 31] . If future studies show the efficacy of first-line lopinavir/ritonavir efficacy among sdNVP-exposed women to be at the lower end of this range, lopinavir/ ritonavir cost-effectiveness will be lower than trial 1 data suggest.
The cost-effectiveness of lopinavir/ritonavir is also influenced by two long-term ARToutcomes: the efficacy of second-line ART and the risk of 'late' virologic failure after 24 weeks on ART. A primary concern about the use of first-line lopinavir/ritonavir in women with sdNVP exposure is the feasibility of 'returning' to nevirapinebased second-line ART. Because second-line ART in many settings is often protease inhibitor-based [21] , the 24-week suppressive efficacy of second-line NNRTIbased ART is infrequently described. Available estimates are from observational studies in the UK [26] and Durban, South Africa [27] (Appendix), and range from 16.0 to 45.0%. Theoretically, the lowest published second-line nevirapine efficacies may be applicable to OCTANE participants. If women randomized to nevirapine failed first-line ART due to sdNVP-associated resistance, but those randomized to lopinavir/ritonavir failed first-line ART due to poor adherence, this poor first-line adherence may predict poor adherence to, and low efficacy of, the second-line nevirapine-based regimen that follows first-line nevirapine [27] . Alternatively, the true efficacy of second-line nevirapine for OCTANE participants may be higher than the published values, because OCTANE participants initiated completely novel second-line regimens, including two NRTIs to which they had no previous exposure. In addition, greater time since sdNVP exposure in those initiating first-line lopinavir/ritonavir (due to time elapsed before initiating second-line nevirapine) might improve second-line nevirapine efficacy due to attenuation of single-dose nevirapine-associated NNRTI resistance with time [5, 32] . Although the base case estimate (43%) was chosen to be conservative with regard to these assumptions, we find that first-line lopinavir/ritonavir remains 'very costeffective' unless the 24-week efficacy of the subsequent second-line nevirapine-based regimen is below 13%, lower than the published estimates of 16-45 [26, 27] . Similarly, the efficacy of second-line lopinavir/ritonavir (following first-line nevirapine) must exceed 87% for the first-line lopinavir/ritonavir strategy to no longer be 'very cost-effective,' also outside published ranges (45-75% [28, [33] [34] [35] [36] ).
In addition, trial 1 data demonstrated substantially greater 'late' failure risks for NVP (10.61%/year) than lopinavir/ ritonavir (2.84%/year). Sensitivity analyses (Fig. 1 ) highlight that if the risk of 'late' failure on lopinavir/ritonavir approached or exceeded that of nevirapine, lopinavir/ ritonavir would be less cost-effective. However, when data from other published trials are used to determine 'late' failure risks, reported ranges for NNRTI (<0-17.60%/year) and protease inhibitor (<0-29.84%/ year)-based ART are wide and overlapping [26, [28] [29] [30] [35] [36] [37] [38] . As interest in protease inhibitor-based firstline ART increases for men and for women without sdNVP exposure in resource-limited settings [30, 39] , data on late outcomes of first-line ART and virologic suppression on second-line ART should remain a research priority.
The impact of NNRTI resistance is reflected in the OCTANE subgroups stratified by NNRTI resistance at baseline and time between sdNVP exposure and ART initiation. Comparing the primary trial endpoint (virologic failure or death), lopinavir/ritonavir was markedly superior to nevirapine among the entire trial 1 cohort and among women with detectable NNRTI resistance at ART initiation. However, among participants without detectable NNRTI resistance, lopinavir/ritonavir conferred a smaller, nonsignificant benefit over nevirapine [10] . As a result of this trial-reported decrease in relative clinical effectiveness, we find that first-line lopinavir/ ritonavir becomes less cost-effective as the population prevalence of NNRTI resistance decreases. Additionally, as time between sdNVP exposure and ART initiation increases, sdNVP-associated resistance fades from detection [32] , and the efficacy of NNRTI-based ART improves [5, 8, 32, 40, 41] . Because the superiority of lopinavir/ ritonavir compared to nevirapine similarly faded with time in OCTANE, we find that first-line lopinavir/ ritonavir is most cost-effective for women with recent sdNVP exposure, 'dominating' first-line nevirapine if ART is initiated within 6-12 months after sdNVP.
The analysis suggests that genotypic resistance testing at ART initiation is a cost-effective strategy for selection of first-line ART after sdNVP exposure. However, if resistance testing or first-line lopinavir/ritonavir is not readily available, efforts to reduce sdNVP-associated resistance remain critical. This analysis focuses on women who have already been exposed to sdNVP and who will require ART in the near future [2, 5, 6] . Expansion of more effective, non-sdNVP-based antiretroviral regimens for the PMTCT [11, 42] will eventually lead to sdNVP exposure in fewer women. Similarly, improved access to HIV diagnosis early in pregnancy will reduce the number of women who present for PMTCT services in labor and thus require sdNVP [43] . When available, the recommended administration of dual-NRTI 'tails' following sdNVP may further reduce sdNVP-associated resistance by up to 80% [11, 42, 44] . Finally, more widespread access to ART for women with advanced HIV disease, as currently recommended by the WHO [11] and the South African National Department of Health [3] , will further reduce the number of women exposed to sdNVP. Each of these interventions will thereby help to preserve the effectiveness of inexpensive, NNRTI-based ART for HIV-infected women after delivery [40, 45] .
There are four primary limitations to this analysis. First, although clinical and cost data from South Africa may not be generalizable to all settings in which sdNVP is used, we tested a wide range of ART availability, monitoring strategies, and drug costs. These had no substantial impact on policy conclusions unless the most unfavorable values for first-line lopinavir/ritonavir were incorporated simultaneously. Second, interventions deemed 'very costeffective' by WHO-recommended, GDP-based guidelines in South Africa, a middle-income country, may not be considered so in many other countries where sdNVP continues to be widely used [18, 46] . Third, application of trial 2 results (non-sdNVP-exposed women) [30] to the trial 1 cohort reduces lopinavir/ritonavir cost-effectiveness. However, trial 2 results may not be extrapolable to sdNVP-exposed women, due to notable differences in the trial 1 and 2 cohorts (Appendix), and trial 2 lopinavir/ ritonavir 24-week efficacy and 'late' failure must be applied simultaneously to impact the cost-effectiveness of lopinavir/ritonavir compared to nevirapine. Finally, by convention, cost-effectiveness analyses assume a lifetime perspective [17] . Model parameters reflecting current practice, including availability of second and third-line ART and prevalence of sdNVP-associated resistance, may be inappropriate for the distant future. We therefore projected 2-5-year clinical outcomes and costs. These validated short-term estimates may inform the design of clinical trials and may assist national HIV programs and funders planning near-term HIV-related budgets.
Conclusion
Among sdNVP-exposed South African women similar to OCTANE participants, initiating nevirapine-based ART is cost-saving in the short term, and very cost-effective in the long term, compared to no ART. Initiating lopinavir/ ritonavir-based ART improves survival further and is very cost-effective in South Africa, compared to initiating nevirapine-based ART. On the basis OCTANE trial 1 data, initial lopinavir/ritonavir-based ART should be recommended for women exposed to sdNVP less than 12 months prior to ART initiation and for women in whom a standard genotype assay detects NNRTIresistant HIV. When resources permit, lopinavir/ritonavir should also be recommended for women exposed 12-24 months prior and for sdNVP-exposed women for whom timing and resistance information is unknown.
